The ErmE methyltransferase from the erythromycin-producing actinomycete Saccharopolyspora erythraea dimethylates the N-6 position of adenine 2058 in domain V of 23S rRNA. This Many antibiotics inhibit the growth of bacteria by binding to ribosomes and thereby blocking protein synthesis (8, 29) . The target sites of these antibiotics lie primarily within the rRNA (3). Mutations or modifications at these specific sites in the rRNA can consequently confer drug resistance (3). The macrolide antibiotic erythromycin blocks protein synthesis by interacting with the peptidyltransferase center in 23S rRNA (8). This drug is synthesized by the gram-positive bacterium Saccharopolyspora erythraea (formerly Streptomyces erythraeus). This organism protects its own ribosomes by expression of a methyltransferase, ErmE, that specifically modifies nucleotide A2058 (24) (standard Escherichia coli system of numbering) by the addition of two methyl groups at the adenosine N-6 position (25). Nucleotide A2058 is within the peptidyltransferase center of 23S rRNA (Fig. 1) , and its modification confers resistance to macrolide, lincosamide, and streptogramin B (MLS) antibiotics. Numerous other bacteria, including pathogenic species, attain MLS resistance by the same mechanism (6, 31).
Many antibiotics inhibit the growth of bacteria by binding to ribosomes and thereby blocking protein synthesis (8, 29) . The target sites of these antibiotics lie primarily within the rRNA (3) . Mutations or modifications at these specific sites in the rRNA can consequently confer drug resistance (3) . The macrolide antibiotic erythromycin blocks protein synthesis by interacting with the peptidyltransferase center in 23S rRNA (8) . This drug is synthesized by the gram-positive bacterium Saccharopolyspora erythraea (formerly Streptomyces erythraeus). This organism protects its own ribosomes by expression of a methyltransferase, ErmE, that specifically modifies nucleotide A2058 (24) (standard Escherichia coli system of numbering) by the addition of two methyl groups at the adenosine N-6 position (25) . Nucleotide A2058 is within the peptidyltransferase center of 23S rRNA (Fig. 1) , and its modification confers resistance to macrolide, lincosamide, and streptogramin B (MLS) antibiotics. Numerous other bacteria, including pathogenic species, attain MLS resistance by the same mechanism (6, 31) .
Methyltransferases conferring MLS resistance specifically modify 23S rRNA position 2058 in phylogenetically diverse bacterial 23S rRNA (24) . The 23S rRNAs of all bacteria conform to the same 'overall secondary structure model comprising six domains (9, 18) . Nucleotide interactions within and among the domains determine the tertiary conformation of the molecule (2, 10, 14) , which is also phylogenetically conserved. There is divergence in most of the primary structure of the molecule, although regions that are unpaired in the present secondary-structure model, such as the peptidyltransferase loop ( Fig. 1) , are well conserved (7, 9, 15) . It is not presently known which conserved but distinctive structural features of the rRNA are specifically recognized by the methyltransferase.
In this study, the S. erythraea ermE gene has been cloned into vectors suitable for inducible expression in E. coli. The in vivo activity of the methyltransferase has been investigated by establishing the levels of MLS resistance conferred, as well as by assaying the degree of dimethylation at A2058 of 23S rRNA. A highly inducible plasmid construction has been used to express substantial quantities of the enzyme for isolation and purification. The concentrated enzyme functions in vitro and has been used to determine structural features of 23S rRNA that are required for recognition and methylation.
MATERIALS AND METHODS
Construction of plasmids for methyltransferase expression. Cell transformation with plasmids (11) , DNA isolation, and gel electrophoresis (21) were performed by standard procedures. Enzymes used for DNA manipulations were from Biolabs, Boehringer Mannheim, and U.S. Biochemicals and were used according to the suppliers' recommendations. The cloning of the ermE gene into suitable vectors is outlined in Fig. 2 (1, 28) was first inserted after the lac promoter in pUC19. The 280-bp BamHI fragment between the lac promoter and the start of ermE was then deleted, bringing the gene closer to the promoter and providing a well-defined translation start (plasmid pUCM1). Expression of the methyltransferase from this construction produces a translational fusion extended at the N-terminal end by 18 amino acids originating from lacZ and the pUC polylinker sequences.
After establishing that plasmid pUCM1 conferred erythromycin resistance (as described below), the lac-ernE gene fusion was excised on a 1.4-kb TfiI fragment and was inserted into plasmid pJK1 to generate pREK47. These two latter plasmids are derivatives of vectors constructed by Larsen et 
Secondary structure of the peptidyltransferase region within domain V of E. coli 23S rRNA (18) . The position of ErmE dimethylation at A2058 is indicated. The circled nucleotides are sites of mutations conferring resistance to antibiotics that inhibit protein synthesis (for a review, see references 4 and 30) . The annealing site of the 3' end of primer 2060, used to quantify the degree of modification at A2058, is also shown.
permits transcription from the lambda PR promoter into the plasmid repA gene (Fig. 2) . For our studies, both pJK1 and pREK47 were equipped with the aph gene conferring kanamycin resistance.
Bacterial strains and growth conditions. E. coli DH1 (21) was used throughout the study. Cells were grown in LuriaBertani medium (21) ; for plasmid-transformed cells, ampicillin (Sigma) at 100 ,ug/ml or kanamycin (Sigma) at 50 ,ug/ml was added to select for pUC derivatives and Rl derivatives, respectively. The resistance conferred by the methyltransferase to the antibiotics erythromycin (Sigma) and clindamycin (Upjohn) was estimated by spreading 50 ,ul of a methyltransferase associates (25), were pelleted as described above. The methyltransferase was washed from the ribosomes by resuspension in buffer A with 1 M NH4C1 and was kept on ice for 5 h before the ribosomes were repelleted by centrifugation. The supernatant was dialyzed against buffer A without NH4Cl, precipitating the methyltransferase together with minor amounts of other proteins. The precipitant was recovered by centrifugation and was redissolved in buffer A to yield active methyltransferase that is considerably concentrated and purified.
In vitro transcription of domains IV to VI of 23S rRNA. A DNA fragment encoding a T7 promoter followed by a Stul site was inserted into the SphI-PstI polylinker sites of plasmid pUC19. E. coli 23S rRNA gene fragments were formed by restriction endonuclease and Bal 31 exonuclease digestion (16) and were cloned into the StuI site. The fragments encode 23S rRNA domain IV plus domain V (from positions 1647 to 2624), domain V plus domain VI (from positions 2000 to 2904), or domain V alone (from positions 2000 to 2624). These constructions were kindly provided by Roger Garrett. Runoff transcripts of the 23S rRNA domains were formed in vitro on BamHI-linearized plasmid templates with T7 RNA polymerase (Promega) under conditions recommended by the supplier. RNA transcripts were extracted with phenol and chloroform and were precipitated with ethanol.
In vitro methylation assay. ErmE methyltransferase modification of rRNA (isolated from plasmid-free cells) was investigated under a variety of conditions. Reactions were carried out in 50 to 100 ,ul of HEPES (N-2-hydroxyethylpiperazine- N'-2-ethanesulfonic acid), Tris, or cacodylate buffers at pHs from 6.5 to 7.8 and at temperatures from 0 to 65°C. The reaction mixtures contained 2 to 20 mM MgCl2 (or 5 mM EDTA and no magnesium), 100 to 300 mM monovalent cations in the form of NH4Cl or KCl, and 6 mM ,-mercaptoethanol. All assays contained S-adenosylmethionine. Different RNAs were compared directly under the following set of standard conditions to ascertain their suitability as methyltransferase substrates. Naked RNA was enabled to fold into its native conformation by warming to 50°C for 5 min and slow cooling to 30°C prior to reactions. Ribosomes or 50S subunits (4 ,ig), 2 ,ug of rRNA, or 0.5 ,ug of T7-transcribed RNA domains were incubated in 75 ,ul of buffer A for 45 min at 30°C with 1 mM S-adenosylmethionine and 0.1 ,ug of purified methyltransferase. The reactions were stopped by phenol and chloroform extraction followed by ethanol precipitation. The degree of dimethylation was assayed by extension from the 2060 primer.
Domain V in 23S rRNA and in T7 RNA polymerase transcripts was additionally screened with primers complementary to sequences from 2275 to 2291 and 2603 to 2619 and from 2677 to 2694 (for 23S rRNA only). Reverse transcriptase extensions with 1 mM dATP, dCTP, dGTP, and dTTP (26) were designed to detect any additional nonspecific RNA modifications.
RESULTS
Methyltransferase expression estimated by antibiotic resistance. ErmE methyltransferase modifies 23S rRNA, conferring resistance to MLS antibiotics. Cells harboring the plasmids constructed in this study were tested to determine whether the ermE gene is expressed in sufficient amounts to confer resistance. The antibiotics erythromycin (a macrolide) and clindamycin (a lincosamide) were chosen for this purpose, as both pass through the E. coli outer membrane. The minimal concentration of clindamycin or erythromycin required to inhibit plasmid-free E. coli DH1 cells is 50 ,ug/ml (Table 2) . Plasmid pJK1 (lacking ermE) does not alter the drug sensitivity of the strain, whereas expression of ermE from the single-copy plasmid pREK47 confers a clear increase in tolerance of the drugs. Increased levels of active methyltransferase in the cells containing higher-copy-number plasmids (pUC31 and pUCM1) are reflected by the greater levels of drug resistance ( these transcription products, as illustrated in Fig. 3 . Although ErmE has been shown to exclusively dimethylate A2058 in Bacillus stearothermophilus 23S rRNA (24) , it cannot be ruled out that monomethylation at this site occurs in E. coli rRNA (12) . As N-6 monomethylation of adenine does not stop reverse transcription (33) , the values given here should be viewed as minimal estimations of the modification at A2058.
The levels of A2058 modification in cells grown under a range of conditions were estimated. When grown at 35°C under noninducing conditions, cells harboring the single-copy plasmid pJEK47 produce only enough methyltransferase to modify 3% of the rRNA (Fig. 3) . Modification of the rRNA is increased either by the addition of IPTG (isopropyl-13-Dthiogalactopyranoside), which removes transcriptional control of the lac promoter, or by temperature induction of plasmid replication. The latter method gives an appreciable amplification of the number of copies of ermE per cell, leading to modification of 70% of the 23S rRNA molecules (Fig. 3 ).
Extraction and purification of the methyltransferase. The methyltransferase was isolated in a concentrated form to investigate its activity in vitro. The erinE gene in plasmid pREK47 is fairly well shut down before induction, but it can be induced by a temperature shift to 42°C to produce large amounts of the enzyme. The demonstration of this by the rRNA modification levels (Fig. 3) was subsequently confirmed by protein analysis on sodium dodecyl sulfate (SDS) gels (Fig.  4) . At 35°C, very little of the methyltransferase is present, but after heat induction, the cells contain considerable amounts of the enzyme. The methyltransferase associates with ribosomes, which are readily isolated by centrifugation, and the enzyme is released by a high-salt wash (25) . This extract dimethylates E. coli 23S rRNA in vitro. We found that further purification is achieved by desalting the extract, which leads to preferential precipitation of the methyltransferase and exclusion of most of the other cellular proteins (Fig. 4) . The methyltransferase was dissolved once more in buffer A containing 100 mM NH4Cl, and this purified extract was used for the in vitro methylation experiments described here.
The cloned methyltransferase (calculated molecular weight, 43,600) migrates slightly more slowly than the ovalbumin marker protein (43,000 Da) on SDS gels (Fig. 4) . The amount of methyltransferase was estimated by SDS gel electrophoresis to be above 70% of the total protein in the purified extract.
In vitro methylation assay. The methyltransferase modifies A2058 in its 23S rRNA substrate over a wide range of conditions in vitro. The enzyme shows activity in all the buffers tested from pH 6.5 to 7.8, with 100 to 300 mM monovalent cations and 2 to 20 mM MgCl2. In buffer A, the enzyme dimethylates 23S rRNA well at 20, 30, and 37°C but only to a minor degree at 14°C, and no activity was observed at 0, 55, or 65°C. In cacodylate buffer at pH 6.5, however, a slight amount of activity was obtained at 0°C. The methyltransferase retains its activity for over 1 year when stored at -80°C in buffer A. RNA substrates for in vitro methylation. Naked 23S rRNA, extracted either from cell lysates or from fractionated ribosomal particles, is a suitable substrate for the methyltransferase. However, rRNA that is assembled within 50S subunits or 70S ribosomes is not accessible for modification by the enzyme (data not shown).
Truncated portions of 23S rRNA containing the methyltransferase target site were transcribed and purified in vitro. Transcripts spanning 23S RNA domains IV and V, domains V and VI, or domain V alone were all readily modified in vitro at A2058 by ErmE, as shown by primer extension analysis. The kinetics of in vitro methylation of intact 23S rRNA and the kinetics of methylation of the domain V transcript are extremely similar (Fig. 5) . Furthermore, both the intact 23S rRNA and the domain V transcript could be modified in buffer without magnesium and with 5 mM EDTA (Fig. 5) .
Specificity for A2058. After in vitro methylation of the RNA substrates by ErmE, the rest of domain V was screened for additional modifications. Screening in buffer A under the conditions described in Materials and Methods revealed no additional modifications. However, under more extreme conditions with the use of three times the amount of ErmE and S-adenosylmethionine and longer incubation times, a band was detected at A2225 in the domain V RNA fragment. This effect does not occur in the intact 23S rRNA and only first becomes apparent in the domain V transcript when the RNA is virtually completely methylated at A2058. ErmE specifically modifies 23S rRNA A2058 in vitro, as previously shown with radioactively labeled S-adenosylmethionine (24) . rRNA that has been assembled into 50S subunits or ribosomes is not modified by ErmE in vitro, in accordance with results for Bacillus 50S subunits (24) . This suggests that ribosomal proteins either obscure or alter the conformation of nucleotide A2058 and/or other rRNA structures that are required for methyltransferase recognition. Presumably, the enzyme is also incapable of methylating assembled subunits in vivo. As ribosomal proteins attach to rRNA before its transcription is complete (22) , the 23S rRNA precursor is already being assembled from its 5' regions before domain V (containing A2058) has been transcribed. It follows therefore that much of the 23S rRNA structure is never available for direct interaction with the methyltransferase in vivo. Consistent with this is the demonstration here that most of the 23S rRNA structure is unnecessary for methylation by ErmE.
The RNA transcript comprising domains IV and V is methylated no better than domain V alone, strongly suggesting that domain IV is irrelevant for ErmE interaction. In the case of ErmC, however, footprinting on Bacillus 23S rRNA indicated that this methyltransferase interacts with both domains IV and V (27) . No firm conclusions about differences in ErmC and ErmE interaction with 23S rRNA should yet be drawn, as ligands can give footprints on RNA that extend outside the region of specific contact (20) . For ErmE, there was also no improvement in the degree of methylation of the domain V plus VI transcript compared with the domain V transcript. Within the cell, association of ribosomal proteins with domain V could be well under way before transcription of domain VI is complete. Thus, the rather narrow temporal window in which the enzyme must act in vivo would also argue against the existence of recognition determinants in domain VI.
The methylation of isolated domain V additionally demonstrates that the interactions between domains, which determine the tertiary folding of 23S rRNA (10, 14) , are unnecessary for methyltransferase binding. The requirement for a tertiary structure within 23S rRNA domain V is also brought into question, as methylation could be achieved without magnesium in the presence of EDTA. These conditions have been shown to remove the tertiary structure from tRNA while allowing the four stems of the cloverleaf secondary structure to remain base paired (19) .
The determinants with which ErmE potentially interacts are thus limited to primary and secondary structural elements (and, formally, the magnesium-independent tertiary structure) within domain V. The features recognized by ErmE must fulfill two main criteria: first, they must be conserved in bacteria as diverse as E. coli and S. erythraea, and second, they must be unambiguous (the enzyme modifies only the one site [24] within almost 5,000 nucleotides of bacterial rRNA sequence). The primary and secondary structures around nucleotide A2058 fulfill the first point, as both are phylogenetically well conserved. However, if the second criterion is met solely by recognition of the primary structure, the enzyme would have to interact with a relatively large number of bases in order to attain its high specificity (in 23S rRNA alone, the probability of duplication of a particular 6-base sequence is just over 50% 
